Stock Taper
ANIP
ANI PHARMACEUTICALS, INC.
NASDAQ
$73.89
▲ UP 2.65% (1.91)

KEY STATISTICS

Market Cap$1.64 B
52w High$97.00
52w Low$69.58
Dividend Yield—
Frequency—
P/E8.99
Volume537.54K
Shares Out.22.73M

COMPANY

LEADERSHIP

Nikhil Lalwani
CHIEF EXECUTIVE
Nikhil Lalwani

COMPENSATION 2026

Salary$837,409
Stock Awards$7,848,711
Incentive Plan Pay$1,572,500
All Other Comp.$20,000
Total$10,278,620

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 5, 2000
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
970

PRICE TARGET

Target High$119.00
Target Low$85.00
Target Median$97.00
Target Consensus$99.50

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.$280.25M
NOV
6
FRI

SPLIT RECORD

DATETYPERATIO
2013-07-18Reverse1:6
2012-06-04Reverse1:6
2002-06-03Reverse1:10

ETFS HOLDING THIS STOCK

ETFS HOLDING
198
LISTED HERE
10
RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
47.46%
HOLDERS
430
TOP 8 OF 430 · RANKED BY POSITION SIZE

PRICE

$73.89 ▲ UP 2.65% (+$1.91)
OVERLAYS
$72.00$72.75$73.50$74.259:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM73.89

About ANI Pharmaceuticals, Inc.

https://www.anipharmaceuticals.com ↗

ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals, including controlled substances and specialty products, primarily in the U.S. and Canada, serving various distribution channels since 2...

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT ANI PHARMACEUTICALS, INC. IS KNOWN FOR

Purified Cortrophin Gel
Purified Cortrophin Gel

Purified Cortrophin Gel, an injectable therapy for autoimmune and inflammatory disorders like MS, RA, and nephrotic syndrome, is a key growth driver for ANI Pharmaceuticals' Rare Disease segment, with ongoing FDA-approved delivery innovations.

ANI Pharmaceuticals in 2025

SENTIMENT: + POSITIVE
EARNINGS · AUGUST 2025

ANI Pharmaceuticals Reports Record Q2 2025 Earnings and Raises Full-Year Guidance, Sparking Significant Stock Surge

ANI Pharmaceuticals announced record second-quarter 2025 financial results, with a 53.1% year-over-year increase in net revenues to $211.4 million. The company significantly raised its full-year 2025 guidance, projecting net revenues between $818 million and $843 million and adjusted EPS of $6.98 to $7.35, which led to a more than 19% increase in its stock price on the day of the announcement.

LEADERSHIP STRATEGY · THROUGHOUT 2025 · IN PROGRESS

ANI Pharmaceuticals Solidifies Rare Disease as Primary Growth Engine, Projecting Segment to Comprise Half of 2025 Revenue

Throughout 2025, ANI Pharmaceuticals' leadership team has intentionally and successfully executed a strategy to elevate its Rare Disease business as the company's primary growth and revenue driver. This strategic focus, centered on the significant sales growth of Purified Cortrophin® Gel and newly acquired ophthalmology products, has fundamentally shifted the company's business composition and is projected to account for approximately 50% of total net revenues for the year.

Latest News

DEFENSE WORLD · OCT 6, 2026

Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)

Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity4
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book2
Overall Score3

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
TEVA$39.18COMPARE
VTRS$17.25COMPARE
RDY$12.23COMPARE
AMRX$19.54COMPARE
BHC$6.08COMPARE
AMPH$26.05COMPARE
HROW$30.62COMPARE
COLL$22.05COMPARE

INSIDER TRADES

★
OFFICER: SVP & CFO
CAREY STEPHEN P.
Sale · 2.9K shares
2026-09-29
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Lalwani Nikhil
Sale · 5.4K shares
2026-09-15
★
OFFICER: SR. VP, GENERAL COUNSEL & SEC.
Cook Meredith
Sale · 500 shares
2026-09-14
★
DIRECTOR
Thoma Jeanne
Sale · 1.0K shares
2026-09-11